Ontology highlight
ABSTRACT: Rationale
CSF1R tyrosine kinase inhibitors (TKI) and antibodies yield response rates and tumor control in patients with diffuse type tenosynovial giant cell tumors (dTGCT). The long term management of patients with dTGCT treated with TKI is however not known.Patients and methods
We conducted a retrospective single center study on the 39 patients with advanced and/or inoperable dTGCT referred to the Centre Leon Berard for a medical treatment. The clinical characteristics and treatments of patients who had received at least one line of CSF1R TKI or Ab was collected from the electronic patient records and analyzed, after this study was approved by the Institutional Review Board of the Centre Leon Berard. Statistics were conducted using SPSS 23.0.Results
Thirty-nine pat
SUBMITTER: Brahmi M
PROVIDER: S-EPMC7239463 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature